Aparna Kamat, MD

Associate Professor of Clinical Obstetrics and Gynecology, Institute for Academic Medicine
Houston Methodist
Weill Cornell Medical College


Dr. Aparna Kamat is the director of the Division of Gynecologic Oncology for Houston Methodist and is currently the section leader for the Gynecologic Oncology service line. After completing medical training in India, Dr. Kamat completed her residency in OB/GYN at West Virginia University where she served as chief resident.

She completed her fellowship training in Gynecologic Oncology at the MD Anderson Cancer Center. During her fellowship, she received multiple awards for her research in ovarian cancer and endometrial cancer including the Virginia K. Pierce award and the Asche Murray fellowship. She also received the prestigious BIRCWH award from the N.I.H. for her research in biomarkers for ovarian cancer. Dr. Kamat currently is the principle investigator for the Gynecologic Oncology Group Clinical Trials Program at Houston Methodist and offers several state-of-the-art clinical trials for patients with gynecologic malignancies.

Her areas of expertise are robotic and minimally invasive surgical options for women with gynecologic cancers and complex pelvic disease. Her other clinical interests include hereditary risk assessment and treatment of gynecologic malignancies.


Non-16/18 high-risk HPV infection predicts disease persistence and progression in women with an initial interpretation of LSIL
Lyons, YA, Kamat, AA, Zhou, H, Mody, DR, Schwartz, MR, Hobday, C & Ge, Y 2015, Cancer Cytopathology, vol 123, no. 7, pp. 435-442. DOI:

Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma
Gillet, JP, Calcagno, AM, Varma, S, Davidson, B, Elstrand, MB, Ganapathi, R, Kamat, AA, Sood, AK, Ambudkar, SV, Seiden, MV, Rueda, BR & Gottesman, MM 2012, Clinical Cancer Research, vol 18, no. 11, pp. 3197-3206. DOI:

Ovarian cancer
Bhosale, P, Kamat, A & Eifel, PJ 2012, . in Oncologic Imaging: A Multidisciplinary Approach. Elsevier Health Sciences, pp. 455-478. DOI:

Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer
Coleman, RL, Duska, LR, Ramirez, PT, Heymach, JV, Kamat, AA, Modesitt, SC, Schmeler, KM, Iyer, RB, Garcia, ME, Miller, DL, Jackson, EF, Ng, CS, Kundra, V, Jaffe, R & Sood, AK 2011, The Lancet Oncology, vol 12, no. 12, pp. 1109-1117. DOI:

Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors
Liggett, TE, Melnikov, A, Yi, Q, Replogle, C, Hu, W, Rotmensch, J, Kamat, A, Sood, AK & Levenson, V 2011, Gynecologic Oncology, vol 120, no. 1, pp. 113-120. DOI:

Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer
Merritt, WM, Kamat, AA, Hwang, JY, Bottsford-Miller, J, Lu, C, Lin, YG, Coffey, D, Spannuth, W, Nugent, E, Han, LY, Landen, CN, Nick, AM, Stone, RL, Coffman, KT, Bruckheimer, E, Broaddus, R, Gershenson, DM, Coleman, RL & Sood, AK 2010, Cancer Biology and Therapy, vol 10, no. 12, pp. 1306-1314. DOI:

Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis
Sood, AK, Armaiz-Pena, GN, Halder, J, Nick, AM, Stone, RL, Hu, W, Carroll, AR, Spannuth, WA, Deavers, MT, Allen, JK, Han, LY, Kamat, AA, Shahzad, MMK, McIntyre, BW, Diaz-Montero, CM, Jennings, NB, Lin, YG, Merritt, WM, DeGeest, K, Vivas-Mejia, PE, Lopez-Berestein, G, Schaller, MD, Cole, SW & Lutgendorf, SK 2010, Journal of Clinical Investigation, vol 120, no. 5, pp. 1515-1523. DOI:

Plasma cell-free DNA in ovarian cancer: An independent prognostic biomarker
Kamat, AA, Baldwin, M, Urbauer, D, Dang, D, Han, LY, Godwin, A, Karlan, BY, Simpson, JL, Gershenson, DM, Coleman, RL, Bischoff, FZ & Sood, AK 2010, Cancer, vol 116, no. 8, pp. 1918-1925. DOI:

Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer
Merritt, WM, Nick, AM, Carroll, AR, Lu, C, Matsuo, K, Dumble, M, Jennings, N, Zhang, S, Lin, YG, Spannuth, WA, Kamat, AA, Stone, RL, Shahzad, MMK, Coleman, RL, Kumar, R & Sood, AK 2010, Molecular Cancer Therapeutics, vol 9, no. 4, pp. 985-995. DOI:

Frequent downregulation of miR-34 family in human ovarian cancers
Corney, DC, Hwang, CI, Matoso, A, Vogt, M, Flesken-Nikitin, A, Godwin, AK, Kamat, AA, Sood, AK, Ellenson, LH, Hermeking, H & Nikitin, AY 2010, Clinical Cancer Research, vol 16, no. 4, pp. 1119-1128. DOI:

Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma
Merritt, WM, Danes, CG, Shahzad, MMK, Lin, YG, Kamat, AA, Han, LY, Spannuth, WA, Nick, AM, Mangala, LS, Stone, RL, Hye, SK, Gershenson, DM, Jaffe, RB, Coleman, RL, Chandra, J & Sood, AK 2009, Cancer Biology and Therapy, vol 8, no. 16, pp. 1596-1603.

EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer
Kamat, AA , Coffey, D, Merritt, WM, Nugent, E, Urbauer, D, Lin, YG, Edwards, C, Broaddus, R, Coleman, RL & Sood, AK 2009, Cancer, vol 115, no. 12, pp. 2684-2692. DOI:

Functional significance of VEGFR-2 on ovarian cancer cells
Spannuth, WA, Nick, AM, Jennings, NB, Armaiz-Pena, GN, Mangala, LS, Danes, CG, Lin, YG, Merritt, WM, Thaker, PH, Kamat, AA, Han, LY, Tonra, JR, Coleman, RL, Ellis, LM & Sood, AK 2009, International Journal of Cancer, vol 124, no. 5, pp. 1045-1053. DOI:

Erythropoeisis-stimulating agents (ESAs) in cervix cancer: The "black box" paradox
Kamat, AA & Coleman, RL 2009, Cancer Biology and Therapy, vol 8, no. 1, pp. 18-20.

Dicer, Drosha, and outcomes in patients with ovarian cancer
Merritt, WM, Lin, YG, Han, LY, Kamat, AA, Spannuth, WA, Schmandt, R, Urbauer, D, Pennacchio, LA, Cheng, JF, Nick, AM, Deavers, MT, Mourad-Zeidan, A, Wang, H, Mueller, P, Lenburg, ME, Gray, JW, Mok, S, Birrer, MJ, Lopez-Berestein, G, Coleman, RL, Bar-Eli, M & Sood, AK 2008, New England Journal of Medicine, vol 359, no. 25, pp. 2641-2650. DOI:

Tumor-selective response to antibody-mediated targeting of avß3 integrin in ovarian cancer
Landen, CN, Kim, TJ, Lin, YG, Merritt, WM, Kamat, AA, Han, LY, Spannuth, WA, Nick, AM, Jennnings, NB, Kinch, MS, Tice, D & Sood, AK 2008, Neoplasia, vol 10, no. 11, pp. 1259-1267. DOI:

Targeting Aurora kinase with MK-0457 inhibits ovarian cancer growth
Lin, YG, Immaneni, A, Merritt, WM, Mangala, LS, Kim, SW, Shahzad, MMK, Tsang, YTM, Armaiz-Pena, GN, Lu, C, Kamat, AA, Han, LY, Spannuth, W, Nick, AM, Landen, CN, Wong, KK, Gray, MJ, Coleman, RL, Bodurka, DC, Brinkley, WR & Sood, AK 2008, Clinical Cancer Research, vol 14, no. 17, pp. 5437-5446. DOI:

HLA class i antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma
Han, L, Fletcher, MS, Urbauer, DL, Mueller, P, Landen, CN, Kamat, AA, Lin, YG, Merritt, WM, Spannuth, WA, Deavers, MT, De Geest, K, Gershenson, DM, Lutgendorf, SK, Ferrone, S & Sood, AK 2008, Clinical Cancer Research, vol 14, no. 11, pp. 3372-3379. DOI:

Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth
Merritt, WM, Lin, YG, Spannuth, WA, Fletcher, MS, Kamat, AA, Han, LY, Landen, CN, Jennings, N, De Geest, K, Langley, RR, Villares, G, Sanguino, A, Lutgendorf, SK, Lopez-Berestein, G, Bar-Eli, MM & Sood, AK 2008, Journal of the National Cancer Institute, vol 100, no. 5, pp. 359-372. DOI:

Clinical and biological significance of vascular endothelial growth factor in endometrial cancer
Kamat, AA, Merritt, WM, Coffey, D, Lin, YG, Patel, PR, Broaddus, R, Nugent, E, Han, LY, Landen, CN, Spannuth, WA, Lu, C, Coleman, RL, Gershenson, DM & Sood, AK 2007, Clinical Cancer Research, vol 13, no. 24, pp. 7487-7495. DOI: